Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution... – Containing or obtained from leguminosae
Reexamination Certificate
2007-08-14
2007-08-14
Flood, Michele (Department: 1655)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Containing or obtained from leguminosae
Reexamination Certificate
active
10743250
ABSTRACT:
Provided is a use for Bowman Birk Inhibitor (BBI), as administered in Bowman Birk Inhibitor Concentrate (BBIC), for the treatment of autoimmune diseases in a patient, wherein the disease is characterized by chronic inflammation, such as rheumatoid arthritis; and more particularly for the treatment of those diseases that are characterized by chronic neuroinflammation and/or demyelination, such as Multiple Sclerosis (MS) and Guillain Barre Syndrome (GBS). In addition, the present invention provides methods for using BBI/BBIC to reduce, inhibit, suppress or prevent the chronic inflammation in such patients; and more particularly, to reduce, inhibit, suppress or prevent the chronic neuroinflammation and demyelination that occurs when the patient's nerve tissues are affected by the disease.
REFERENCES:
patent: 4793996 (1988-12-01), Kennedy et al.
patent: 5217717 (1993-06-01), Kennedy et al.
patent: 5338547 (1994-08-01), Kennedy et al.
patent: 5616492 (1997-04-01), Kennedy et al.
patent: 5618679 (1997-04-01), Kennedy et al.
patent: 5961980 (1999-10-01), Kennedy et al.
patent: 6767564 (2004-07-01), Rostami et al.
Atkinson, SJ, Ward, RV, Reynolds, JJ, “Cell-mediated degradation of type IV collagen and gelatin films is dependent on the activation of matrix metalloproteinases,”Biochem. J. 288:605-611 (1992).
Bai, X.F., F.D. Shi, J. Zhu, B.G. Xiao, G. Hedlund, and H. Link, “Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions,”J. Neuroimmunol. 76:177 (1997).
Bar-Or A, Oliveira EM, Anderson DE, Hafler DA, “Molecular pathogenesis of multiple sclerosis,”J. Neuroimmunol. 100:252-259 (1999).
Bever, CT Jr, Rosenberg, GA, “Matrix metalloproteinases; in multiple sclerosis: targets of therapy or markers of injury?”Neurology53:1380-1381 (1999).
Billings PC, “Approaches to studying the target enzymes of anticarcinogenic protease inhibitors,” InProtease Inhibitors as Cancer Chemopreventive Agents, Troll W, Kennedy AR (eds.), New York, Plenum Press, 1993, pp. 191-198.
Billings, PC, Brandon, DL, Habres, JM, “Internalization of the Bowman-Birk protease inhibitor by intestinal epithelial cells,”Eur. J. Canc. 27:903-908 (1991B).
Billings, PC, Clair, WHS, Maki, PA, Kennedy, AR, “Distribution of the Bowman-Birk inhibitor in mice following oral administration,”Canc. Lett. 62:191-197 (1992).
Billings, PC, Habres, JM, Liao, DC,. Tuttle, SW, “Human Fibroblasts Contain a Proteolytic Activity Which Is Inhibited by the Bowman-Birk Protease Inhibitor,”Cancer Res. 50:5539-5543 (1991A).
Birk, Y, “Protease Inhibitors of Plant Origin and the Role of Protease Inhibitors in Human Nutrition,” InProtease Inhibitors as Cancer Chemopreventive Agents. Troll W, Kennedy AR (eds). New York, Plenum Press, 1993, pp. 97-106.
Birk, Y, “Proteinase inhibitors from plant sources,”Meth. Enzymol. 45:695-751 (1975).
Birk, Y, “The Bowman-Birk Inhibitor,”J. Peptide Protein Res. 25:113-134 (1985).
Boccaccio, GL, Steinman, L, “Multiple sclerosis: from a myelin point of view,”J. Neurosci. Res. [vol. 45]:647-654 (1996).
Bowman, DE, “Fractions derived from soybeans and Navy beans which retard tryptic digestion of casein,”Proc. Soc. Exp. Biol. Med. 57:139-140 (1944).
Bowman, DE, “Further identification of bean trypsin inhibiting factors,”Arch. Biochem. Biophys. 16:109-113 (1948).
Brosnan, CR, Caminer, W, Norton, WT, Bloom, BR, “Proteinase inhibitors suppress the development of experimental alleric encephalomyelitis,”Nature285:235-237 (1980).
Brostoff, SW, Burnett, P, Lampert, PW, Eylar, EH, “Isolation and characterization of a protein from sciatic nerve myelin responsible for experimental allergic neuritis,”Nat. New Biol. 235:210-212 (1972).
Clements, JM, Cossins, JA, Wells, GM, Corkill, DJ, Helfrich, Y, Wood, LM, Pigott, R, Stabler, G, Ward, GA, Gearing, AJ, Miller, KM, “Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor,”J. Neuroimmunol. 74:85-94 (1997).
Constantinescu, C.S., Wysocka, M., Hilliard, B., Venyura, E.S., Lavi, E., Trinchieri, G. and Rostami, A., “Antibodies Against IL-12 Prevent Superantigen-Induced and Spontaneous Relapses of Experimental Autoimmune Encephalomyelitis,”J. Immunol. 161:5097-5104 (1998).
Constantinescu, CS, Hilliard, B, Fujioka, T, Bhopale, MK, Calida, D, Rostami, AM, “Pathogenesis of Neuroimmunologic Diseases: Experimental Models,”Immunologic Res. 17:217-227 (1998).
Cuzner ML, Opdenakker G, “Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous systems,”J. Neuroimmunol. 94:1-14 (1999).
Cuzner, MI, Norton, WT, “Biochemistry of demyelination,”Brain Pathol. [vol. 6] 231-242 (1996A).
Dietsch, GN, Hinrichs, DJ, “Mast cell proteases liberate stable encephalitogenic fragments from intact myelin,”Cell. Immunol. 135:541-548 (1991).
Evans et al.,Radiat. Res. 132:259-262 (1992) “Protection against Metastasis of Radiation-Induced Thymic Lymphosarcoma and Weight Loss in C57BI/6NCr1BR Mice by an Autoclave-Resistant Factor Present in Soybeans”.
Frenkel, K, Chrazan, K, Ryan, CA, Wiesner, R, Troll, W, “Chymotrypsin-specific protease inhibitors decrease H202 formation by activated human polymorphonuclear leukocytes,”Carcinogenesis8:1207-1212 (1987).
Fujioka, T., E. Purev, and A. Rostami, “Chemokine mRNA expression in the cauda equina of Lewis rats with experimental allergic neuritis,”J. Neuroimmunol. 97:51 (1999).
Fujioka, T., T. Jimi, B.A. Hilliard, E.S. Ventura, and A. Rostami, “The expression of cytokine mRNA in the cauda equina of Lewis rats with experimental allergic neuritis,”J. Neuroimmunol. 84:223 (1998).
Gijbels, K, Galardy, RE, Steinman, L, “Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases,”J. Clin. Invest. 94:2177-2182 (1994).
Gladysheva, IP, Larionova, NI, Gladyshev, DP, Tikhonova, TV, Kazanskaia, NF, “The classical Bowman-Birk soy inhibitor is an effective inhibitor of human granulocyte alpha-chymotrypsin and cathepsin G,”Biochemistry(Moscow) 59(4):513-518 (1994).
Gold, R., J.J. Archelos, and H.P. Hartung, “Mechanisms of immune regulation in the peripheral nervous system,”Brain Pathol. 9: 343 (1999).
Halonen, T, Kilpelainen, H, Pitkanen, A, Riekkinen, PJ, “Lysosomal hudrolases in cerebrospinal fluid of multiple sclerosis patients,”J. Neurol. Sci. 79:267-274 (1987).
Hartung, HP, Kieseier, BC, “The role of metalloproteinases in autoimmune damage to the central and peripheral nervous system,”J. Neuroimmunol. 107:140-147 (2000).
Hauser, SL, Goodkin, DE, “Multiple Sclerosis and Other Demyelinating Diseases,” InHarrison's Principles of Internal Medicine. Fauci et al. (eds). New York, McGraw-Hill, 1998, pp. 2409-2419.
Hawkins, JV, Emmel, EL, Feuer, A, Nedelman, MA, Harvey, CJ, Klein, HJ, Rozmiarek, J, Kennedy, AR, Lichtenstien, GR, Billings, PC, “Protease activity in a hapten-induced model of ulcerative colitis in rats,”Digestive Diseases and Sciences42:1969-1980 (1996).
Hewson, AY, Smith, T, Leonard, JP, Cuzner, ML, “Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790,”Inflamm. Res. 44:345-349 (1995).
Ibrahim, MZM, Reder, AT, Lawand, R, Takash, W, Sallouh-Khatib, S, “The mast cells of the multiple sclerosis brain,”J. Neuroimmunol. 70:131-138 (1996).
Kennedy, AR, “Anticarcinogenic activity of protease inhibitors: Overview,” InProtease-Inhibitors as Cancer Chemopreventive Agents, Troll, W, Kennedy, AR (eds). New York, Plen
Kennedy Ann
Rostami Abdolmohamad
Flood Michele
McConathy Evelyn H.
Montgomery, McCracken, Walker & Rhoads LLP
The Trustees of the University of Pennsylvania
LandOfFree
Use of Bowman Birk inhibitor for the treatment of multiple... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of Bowman Birk inhibitor for the treatment of multiple..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of Bowman Birk inhibitor for the treatment of multiple... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3863346